BioCentury

8:00 AM GMT, Jan 2, 2012
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Finance

Small-fry squashed

Among last year's best-performing large cap biotechs were an acquiree and an acquirer: HCV play Pharmasset Inc. and Valeant Pharmaceuticals International Inc. Other big cap stocks also did well overall, while investors abandoned their small- and microcap brethren in 2011.

Biotechs valued at less than $200 million as well as those with a $200-$499 million market cap shed almost one-third of their value on the year, while biotechs valued at $5 billion or more added 8% last quarter and on the year (see "Results by Market Cap").

Pharmasset rose 56% in 4Q11 after Gilead Sciences Inc. said it would acquire the HCV play for $11 billion. The shares popped 489% in 2011, having started the year valued at $1.5 billion. Just two years ago, Pharmasset was valued at only $586 million.

Valeant, which is building a specialty pharma business through M&A informed by sophisticated tax and accounting techniques, added 26% on the quarter and 65% on the year.

The company's hostile takeover bid for microcap Ista Pharmaceuticals Inc. drove the ophthalmic play's shares up 104% to $7.05, above Valeant's $6.50 per share cash offer. The offer totals about $327 million, after backing out Ista's debt.

Among the largest biotechs, Biogen Idec Inc. and Amgen Inc. were the big winners last quarter, gaining 18% and 17%, respectively.

Biogen Idec rose in October on Phase III data for BG-12 to treat multiple sclerosis and managed to hold on to most of the gain through year end.

Amgen ran up during a busy December in which it increased its quarterly dividend for 1Q12 to $0.36 from $.0.28; did a $5 billion share buyback; promoted President and COO Robert Bradway to CEO; promoted SVP of Global Development and CMO Sean Harper to EVP of R&D; and disclosed a biosimilar cancer antibody deal with Watson Pharmaceuticals Inc. (see " Elementary, Watson," A17).

Last year's highly anticipated launch stories fell to the bottom of the barrel when it came to performance last quarter. In the group valued above $5 billion, HCV company Vertex Pharmaceuticals Inc. was off 25%. In the $1-$4.9 billion segment, cancer immunotherapy company Dendreon Corp. shed 16%; pulmonary and fibrotic disease company InterMune Inc. lost 38%; and autoimmune, cancer and infectious disease company Human Genome Sciences Inc. fell 42%.

Another former superstar, Amarin Corp. plc, continued to decline last quarter, falling 19% amid ongoing patent issues. In early November, the U.S. Patent and Trademark Office issued a non-final rejection letter for a patent application covering hypertriglyceridemia treatment AMR101, which has a July 26 PDUFA date.

Salix Pharmaceuticals Ltd. was the top gainer last quarter in the $1-$4.9 billion group, adding 62%. It jumped on FDA draft guidance that would delay generic competition for Xifaxan rifaximin to treat travelers' diarrhea and on positive Phase III data for the opioid-induced constipation treatment oral methylnaltrexone. Salix has rights to the OIC product from microcap Progenics Pharmaceuticals Inc., which

Read the full 4734 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.